Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carvedilol phosphate
Drug ID BADD_D00375
Description Carvedilol is a racemic mixture where the S(-) enantiomer is a beta adrenoceptor blocker and the R(+) enantiomer is both a beta and alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.[A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]
Indications and Usage Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.[L7889,L7892]
Marketing Status approved; investigational
ATC Code C07AG02
DrugBank ID DB01136
KEGG ID D03415
MeSH ID D000077261
PubChem ID 9827459
TTD Drug ID D0W9LX
NDC Product Code 12658-0570; 53873-061; 65015-884; 0007-3385; 51407-051; 63629-9634; 69784-714; 12658-0559; 12658-0596; 36974-0067; 16714-229; 51407-050; 51407-052; 69784-385; 69784-713; 72761-003; 0007-3383; 12658-0546; 53873-062; 63629-9632; 63629-9635; 69784-388; 69784-715; 71335-9707; 12658-0595; 12658-0603; 16714-228; 63629-9633; 69784-383; 53873-063; 16714-230; 51407-053; 57664-664; 57664-666; 69784-716; 12658-0412; 12658-0560; 0007-3371; 60505-3679; 63629-8794; 69784-387; 12658-0590; 53873-060; 61187-004; 16714-227; 57664-665; 63415-0127; 0007-3373; 0007-3387; 57664-663
UNII EQT531S367
Synonyms Carvedilol | Carvedilol Hydrochloride | Dilatrend | Querto | Eucardic | Carvedilol, (S)-isomer | Kredex | BM 14190 | BM-14190 | BM14190 | Carvedilol, (R)-isomer | Carvedilol, (+)-isomer | Carvedilol, (+) | Carvedilol, (+-)-isomer | Carvedilol, (-)-isomer | Carvedilol, (-) | Carvedilol, 14C-labeled | 14C-labeled Carvedilol | Carvedilol, 14C labeled | Coropres | Coreg
Chemical Information
Molecular Formula C24H29N2O8P
CAS Registry Number 374779-45-0
SMILES COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.OP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory alkalosis14.01.05.001; 22.02.02.005---
Seizure17.12.03.001--
Sinus congestion22.04.06.001---
Sleep disorder19.02.04.001---
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007---
Thinking abnormal17.02.05.023; 19.10.03.001---
Thrombocytopenia01.08.01.002---
Tinnitus04.04.01.002; 17.04.07.004--
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008--
Urinary incontinence17.05.01.008; 20.02.02.010--
Urticaria10.01.06.001; 23.04.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Hypoacusis04.02.01.006--
Cardioactive drug level increased13.17.01.005---
Affect lability19.04.01.001---
Transaminases increased13.03.04.036---
Dermatitis psoriasiform23.03.14.004---
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.04.028---
Erectile dysfunction19.08.04.001; 21.03.01.007--
Lymphocyte morphology abnormal13.01.06.015---
The 4th Page    First    Pre   4    Total 4 Pages